- Details
- Phillip Koo and Neal Shore discuss the COBRA trial, which investigates the use of 64Cu-SAR-bisPSMA PET imaging in prostate cancer patients with biochemical recurrence (BCR). Dr. Shore, the lead principal investigator, introduces Clarity, an Australian company developing Copper-64-based radiopharmaceuticals. He explains the advantages of Copper-64, such as its long half-life and bivalent structure,...
|
- Details
- Alicia Morgans speaks with Matthew Smith about prognostic and predictive factors in treating metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Smith explains the importance of clinical, imaging, and molecular factors in patient selection for treatment intensification. He highlights that factors like disease volume, manner of presentation, and specific genomic alterations (e.g., PTEN, P53)...
|
- Details
- Alicia Morgans speaks with Louise Emmett about the use of radiopharmaceuticals in prostate cancer, particularly for frail patients. Professor Emmett focuses on dosing radioligand therapy in special situations and managing toxicity, particularly marrow and kidney toxicity. She highlights the need for individualized dosing strategies, noting that current protocols might not adequately treat high-vol...
|
- Details
- Alicia Morgans interviews Ian Davis to discuss the challenges of sequencing treatments for patients with metastatic hormone-sensitive prostate cancer (mHSPC) that have progressed to metastatic castrate-resistant disease (mCRPC). Dr. Davis emphasizes that there is no ideal sequence of treatments but identifies several less-than-ideal approaches. He highlights the importance of achieving maximum ben...
|
- Details
- Maria De Santis discusses managing frail patients with metastatic hormone-sensitive prostate cancer. Dr. De Santis explains the importance of defining frailty, which involves five key factors: unintended weight loss, weakness, low physical activity, difficulty lifting objects, and mobility issues. She highlights the necessity of evaluating frailty using tools like the G8 screening and emphasizes t...
|
- Details
- Oliver Sartor discusses his approach to treating low-volume metastatic prostate. Dr. Sartor emphasizes the importance of molecular imaging, particularly PSMA PET, to define low-volume and oligometastatic disease accurately. He advocates for a "total therapy" approach, combining androgen deprivation, novel hormones, and targeted radiation, including SBRT for metastatic sites and pelvic radiation. D...
|
- Details
- Zach Klaassen discusses the EvoPAR-Prostate 01 trial with Neeraj Agarwal. The trial examines a new PARP inhibitor combined with ARPI in metastatic hormone-sensitive prostate cancer, both in biomarker-positive and -negative populations. Dr. Agarwal explains the rationale based on preclinical data and previous trials like PROpel and TALAPRO-2, showing efficacy in HRR mutation-positive patients and p...
|
- Details
- Alicia Morgans speaks with Joaquin Mateo about his presentation on PARP inhibitors. Dr. Mateo discusses the role of PARP inhibitors in treating metastatic castration-resistant prostate cancer (mCRPC) with BRCA1 or BRCA2 mutations, noting the poor prognosis associated with these mutations but highlighting the effectiveness of PARP inhibitors like olaparib and rucaparib. He explains the differences...
|
- Details
- Alicia Morgans engages with Noel Clarke on the critical issue of bone health in prostate cancer patients, particularly those undergoing androgen deprivation therapy (ADT). Professor Clarke shares findings from the STAMPEDE trial and other studies that highlight the high fracture rates in these patients. He criticizes the reliability of the FRAX scoring system, which was originally developed for a...
|
- Details
- Alicia Morgans interviews Thomas Zilli about the PEACE V study. The study, termed the STORM trial, investigates treatment strategies for patients with oligorecurrent prostate cancer, comparing focalized SBRT, comprehensive irradiation, and salvage lymph node dissection combined with six months of ADT. Aimed at determining the best approach for these patients, the trial specifically looks at metast...
|